LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION April 3, 2023 TO: Honorable Tom Oliverson, Chair, House Committee on Insurance FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: HB118 by Cortez (Relating to health benefit plan coverage for certain tests to detect prostate cancer.), As Introduced Estimated Two-year Net Impact to General Revenue Related Funds for HB118, As Introduced : an impact of $0 through the biennium ending August 31, 2025. The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill. General Revenue-Related Funds, Five- Year Impact: Fiscal Year Probable Net Positive/(Negative) Impact toGeneral Revenue Related Funds2024$02025$02026$02027$02028$0All Funds, Five-Year Impact: Fiscal Year Probable Savings/(Cost) fromSchool Employees UGIP Trust Fund855 Probable Savings/(Cost) fromRETIRED SCHOOL EMP GROUP INSURANCE9892024$0($149,000)2025($267,000)($224,000)2026($278,000)($235,000)2027($290,000)($245,000)2028($302,000)($255,000) Fiscal AnalysisThe bill would prohibit a health benefit plan from charging any premium, copayment, coinsurance, deductible, or any other form of cost sharing for coverage of certain tests to detect prostate cancer, including physical examinations and prostate-specific antigen (PSA) tests. The bill would take effect on September 1, 2023 and apply only to a health benefit plan delivered, issued for delivery, or renewed on or after January 1, 2024. A health benefit plan delivered, issued for delivery, or renewed before January 1, 2024 would be governed by previous law until the renewal date of the plan.
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 88TH LEGISLATIVE REGULAR SESSION
April 3, 2023
TO: Honorable Tom Oliverson, Chair, House Committee on Insurance FROM: Jerry McGinty, Director, Legislative Budget Board IN RE: HB118 by Cortez (Relating to health benefit plan coverage for certain tests to detect prostate cancer.), As Introduced
TO: Honorable Tom Oliverson, Chair, House Committee on Insurance
FROM: Jerry McGinty, Director, Legislative Budget Board
IN RE: HB118 by Cortez (Relating to health benefit plan coverage for certain tests to detect prostate cancer.), As Introduced
Honorable Tom Oliverson, Chair, House Committee on Insurance
Honorable Tom Oliverson, Chair, House Committee on Insurance
Jerry McGinty, Director, Legislative Budget Board
Jerry McGinty, Director, Legislative Budget Board
HB118 by Cortez (Relating to health benefit plan coverage for certain tests to detect prostate cancer.), As Introduced
HB118 by Cortez (Relating to health benefit plan coverage for certain tests to detect prostate cancer.), As Introduced
Estimated Two-year Net Impact to General Revenue Related Funds for HB118, As Introduced : an impact of $0 through the biennium ending August 31, 2025. The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill.
Estimated Two-year Net Impact to General Revenue Related Funds for HB118, As Introduced : an impact of $0 through the biennium ending August 31, 2025. The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill.
The bill would make no appropriation but could provide the legal basis for an appropriation of funds to implement the provisions of the bill.
General Revenue-Related Funds, Five- Year Impact:
2024 $0
2025 $0
2026 $0
2027 $0
2028 $0
All Funds, Five-Year Impact:
2024 $0 ($149,000)
2025 ($267,000) ($224,000)
2026 ($278,000) ($235,000)
2027 ($290,000) ($245,000)
2028 ($302,000) ($255,000)
Fiscal Analysis
The bill would prohibit a health benefit plan from charging any premium, copayment, coinsurance, deductible, or any other form of cost sharing for coverage of certain tests to detect prostate cancer, including physical examinations and prostate-specific antigen (PSA) tests. The bill would take effect on September 1, 2023 and apply only to a health benefit plan delivered, issued for delivery, or renewed on or after January 1, 2024. A health benefit plan delivered, issued for delivery, or renewed before January 1, 2024 would be governed by previous law until the renewal date of the plan.
Methodology
According to the Teacher Retirement System (TRS), eliminating cost sharing for certain tests to detect prostate cancer is estimated to impact less than 0.05 percent of estimated claims under both the TRS-Care and TRS-ActiveCare plans. Additional costs would not increase the statutorily required state contributions to the TRS-Care and TRS-ActiveCare programs for the 2024-25 biennium; therefore, no significant fiscal impact to the General Revenue Fund is anticipated. However, the additional costs may result in the need for additional contributions from the State, employers, or members to the TRS-Care and TRS-ActiveCare programs, or for plan benefit changes.Based on the analysis of the Employees Retirement System, Department of Insurance, Health and Human Services Commission, Texas A&M University System Administrative & General Offices, and the University of Texas System Administration, duties and responsibilities associated with implementing the provisions of the bill could be accomplished by utilizing existing resources.
Local Government Impact
No fiscal implication to units of local government is anticipated.
Source Agencies: b > td > 323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration
323 Teacher Retirement System, 327 Employees Retirement System, 454 Department of Insurance, 529 Health and Human Services Commission, 710 Texas A&M University System Administrative and General Offices, 720 The University of Texas System Administration
LBB Staff: b > td > JMc, AAL, ASA, MMo
JMc, AAL, ASA, MMo